easyJet (EZJ) shares rose 4.49% to 539.7p as airline declares new Director
Today, easyJet announced that Stephen Hester, Non-Executive Chair of easyJet, has joined the Board of Directors of Nordea Bank Abp as Vice Chair with effect from 24 March 2022. He will remain Vice Chair until 1 October 2022 when he succeeds Torbjörn Magnusson as Chair.
Holders Technology (HDT) shares jump 20.00% to 105p as it swings to a profit in FY21
Shares in the supplier of printed-circuit-board materials and lighting-and-control services jumped on Monday after it reported a swing to pre tax profit for FY21 as a result of higher revenue that was boosted by a general improvement in economic conditions over the year.
In the year ended 30 November 2021, the company made a pre tax profit of £0.787m, up from a loss of £0.264m a year earlier. Meanwhile, group revenue for the year rose to £12.4m from £9.8m in FY20, largely as a result of growth in the lighting and control solutions business.
The board has declared a final dividend of 0.5 pence a share, taking the total payout for the year to 3 pence compared with 0.50 pence. Holder’s total payout was boosted by a special dividend of 2 pence due to the sale of certain printed-circuit-board assets earlier this year.
Cambridge Cognition (COG) shares jump 16.05% to 141p as it secures £1m contract
Cambridge Cognition, which develops and markets digital solutions to assess brain health, has won a contract worth just over £1 million with a top 10 pharmaceutical company to provide digital cognitive assessments for a pivotal phase III autoimmune disease trial.
The unnamed top 10 pharmaceutical firm said it has selected Cambridge Cognition as the cognitive assessment provider for its pivotal trial as they believe the Company ‘has the technology and infrastructure to deliver rapid, sensitive cognitive assessments at scale.’
Commenting on this morning’s contract, Matthew Stork, Chief Executive Officer of Cambridge Cognition, highlighted to investors: “Phase III clinical trials are the large, final stage in drug development as pharmaceutical companies can use the results to seek regulatory approval.
Strategically, this contract sees the Company operate in a high growth space with a leading pharmaceutical company that is committed to tackling diseases in this therapeutic area.”
Phoenix Copper (PXC) shares rose 14.42% to 59.5p as it publishes ‘positive’ outlook
The US-focused base and precious metals exploration company has published its results for the year to 31 December 2021 in which it reported that its net assets had increased to $37.78m, up from $13.83m reported in FY20 while losses were unchanged at $0.97m.
Phoenix said it maintains a positive outlook as the metals markets continue to perform well.